Clinical trials
Astrocytoma trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 3 |
| 2005 | 2 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2011 | 2 |
| 2013 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Unknown status | 5 |
| Active, not recruiting | 3 |
| Recruiting | 3 |
| Terminated | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 8 |
| Novartis Pharmaceuticals | 4 |
| University Hospital, Montpellier | 2 |
| Alliance for Clinical Trials in Oncology | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Assistance Publique Hopitaux De Marseille | 1 |
| Bayer | 1 |
| BeiGene USA, Inc. | 1 |
| Centre Hospitalier Universitaire, Amiens | 1 |
| Children's Cancer and Leukaemia Group | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Astrocytoma | 29 |
| Glioblastoma | 14 |
| Glioma | 13 |
| Oligodendroglioma | 12 |
| Central Nervous System Neoplasms | 10 |
| Brain Neoplasms | 8 |
| Gliosarcoma | 6 |
| Ganglioglioma | 3 |
| Glioma, Subependymal | 3 |
| Ependymoma | 2 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.